AstraZeneca: Revenue and EPS summary   9M 2025 % Change Q3 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 41,035 9   9   14,365 11   9   - Alliance ...

Investigational gefurulimab met its primary efficacy endpoint in adults with anti-acetylcholine receptor (AChR) ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia ...

PREVAIL phase III trial of gefurulimab meets its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement from baseline in MG-ADL ...

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and ...

While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...

【阿斯利康】周四宣布，其在研抑制剂Gefurulimab的III期临床试验在重症肌无力患者的日常生活活动方面达到了主要终点。 这家总部位于英国剑桥的制药公司表示，与安慰剂相比，Gefurulimab在第26周时显示出改善，早在第一周就观察到具有临床意义的改善，并持续到第26周。全身型重症肌无力是一种罕见的自身免疫性疾病，其特征是肌肉功能丧失和严重的肌肉无力。 阿斯利康罕见病部门Alexion的研发 ...

这家总部位于英国剑桥的制药公司表示，Gefurulimab在第26周时显示出比安慰剂的改善，早在第一周就观察到具有临床意义的改善，并持续到第26周。全身型重症肌无力是一种罕见的自身免疫性疾病，其特征是肌肉功能丧失和严重的肌肉无力。

(Alliance News) - AstraZeneca PLC on Thursday said phase 3 data regarding its investigational inhibitor gefurulimab met its primary endpoint in myasthenia gravis activities of daily living.